Enfermedad pulmonar intersticial asociada a rituximab. / [Rituximab-induced interstitial lung disease].
Medicina (B Aires)
; 73(4): 343-5, 2013.
Artigo
em Espanhol
| BINACIS
| ID: bin-133008
ABSTRACT
The introduction of the anti-CD20 antibody rituximab into clinical practice has improved substantially the prognosis of a variety of haematological and autoimmune diseases. The interstitial lung disease is one of most serious and potentially fatal complications of rituximab therapy. This diagnosis should be considered in patients who have received the drug and present with dyspnea, fever and cough without clear evidence of infection. We report a case of rituximab-induced interstitial lung disease.
Buscar no Google
Coleções:
Bases de dados nacionais
/
Argentina
Base de dados:
BINACIS
Assunto principal:
Doenças Pulmonares Intersticiais
/
Anticorpos Monoclonais Murinos
/
Antineoplásicos
Tipo de estudo:
Estudo prognóstico
Idioma:
Espanhol
Revista:
Medicina (B Aires)
Ano de publicação:
2013
Tipo de documento:
Artigo